CYP3A5
E905090
CYP3A5 is a liver-expressed cytochrome P450 enzyme that metabolizes various drugs and xenobiotics, contributing to interindividual variability in drug clearance.
All labels observed (1)
| Label | Occurrences |
|---|---|
| CYP3A5 canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T11074719 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CYP3A5 Context triple: [Docetaxel, primaryMetabolismEnzyme, CYP3A5]
-
A.
CYP3A4
CYP3A4 is a major human liver and intestinal enzyme of the cytochrome P450 family responsible for metabolizing a wide range of drugs and xenobiotics.
-
B.
CYP1A2
CYP1A2 is a liver enzyme of the cytochrome P450 family that plays a key role in the metabolism of various drugs and xenobiotics.
-
C.
CYP2B6
CYP2B6 is a human liver cytochrome P450 enzyme that plays a key role in the metabolism of various drugs and xenobiotics.
-
D.
CYP2C19
CYP2C19 is a liver enzyme of the cytochrome P450 family that plays a key role in the metabolism of various drugs, including certain antidepressants, proton pump inhibitors, and antiplatelet agents.
-
E.
CYP2C9
CYP2C9 is a liver enzyme of the cytochrome P450 family that plays a key role in metabolizing various drugs, including many nonsteroidal anti-inflammatory agents and anticoagulants.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: CYP3A5 Target entity description: CYP3A5 is a liver-expressed cytochrome P450 enzyme that metabolizes various drugs and xenobiotics, contributing to interindividual variability in drug clearance.
-
A.
CYP3A4
CYP3A4 is a major human liver and intestinal enzyme of the cytochrome P450 family responsible for metabolizing a wide range of drugs and xenobiotics.
-
B.
CYP1A2
CYP1A2 is a liver enzyme of the cytochrome P450 family that plays a key role in the metabolism of various drugs and xenobiotics.
-
C.
CYP2B6
CYP2B6 is a human liver cytochrome P450 enzyme that plays a key role in the metabolism of various drugs and xenobiotics.
-
D.
CYP2C19
CYP2C19 is a liver enzyme of the cytochrome P450 family that plays a key role in the metabolism of various drugs, including certain antidepressants, proton pump inhibitors, and antiplatelet agents.
-
E.
CYP2C9
CYP2C9 is a liver enzyme of the cytochrome P450 family that plays a key role in metabolizing various drugs, including many nonsteroidal anti-inflammatory agents and anticoagulants.
- F. None of above. chosen
Statements (56)
| Predicate | Object |
|---|---|
| instanceOf |
cytochrome P450 enzyme
ⓘ
drug-metabolizing enzyme ⓘ enzyme ⓘ protein ⓘ |
| affects |
calcineurin inhibitor pharmacokinetics
ⓘ
tacrolimus dose requirements ⓘ |
| alleleCYP3A5*1 | expressor allele ⓘ |
| alleleCYP3A5*3 | non-expressor allele ⓘ |
| alleleCYP3A5*6 | non-functional allele ⓘ |
| alleleCYP3A5*7 | non-functional allele ⓘ |
| contributesTo |
first-pass metabolism of orally administered drugs
ⓘ
interindividual variability in drug clearance ⓘ |
| encodedBy | CYP3A5 gene NERFINISHED ⓘ |
| foundInTaxon | Homo sapiens NERFINISHED ⓘ |
| hasAllele |
CYP3A5*1
ⓘ
CYP3A5*3 NERFINISHED ⓘ CYP3A5*6 NERFINISHED ⓘ CYP3A5*7 NERFINISHED ⓘ |
| hasBiologicalProcess |
drug metabolic process
ⓘ
oxidation-reduction process ⓘ steroid metabolic process ⓘ xenobiotic metabolic process ⓘ |
| hasCofactor | heme ⓘ |
| hasMolecularFunction |
drug binding
ⓘ
monooxygenase activity ⓘ oxidoreductase activity ⓘ |
| highlyExpressedIn | CYP3A5*1 carriers ⓘ |
| inducedBy |
carbamazepine
NERFINISHED
ⓘ
rifampin NERFINISHED ⓘ |
| inhibitedBy |
azole antifungals
ⓘ
macrolide antibiotics ⓘ |
| isClinicallyRelevantFor | pharmacogenomics ⓘ |
| isPolymorphic | true ⓘ |
| locatedIn |
adrenal gland
ⓘ
endoplasmic reticulum membrane ⓘ intestine ⓘ kidney ⓘ liver ⓘ |
| lowOrAbsentExpressionIn | CYP3A5*3 homozygotes ⓘ |
| memberOf |
CYP3A subfamily
NERFINISHED
ⓘ
cytochrome P450 superfamily NERFINISHED ⓘ |
| metabolizes |
carbamazepine
ⓘ
cyclosporine ⓘ endogenous steroids ⓘ midazolam NERFINISHED ⓘ nifedipine NERFINISHED ⓘ protease inhibitors ⓘ statins ⓘ tacrolimus ⓘ |
| orthologInHuman | CYP3A5 NERFINISHED ⓘ |
| regulatedBy |
constitutive androstane receptor
NERFINISHED
ⓘ
pregnane X receptor NERFINISHED ⓘ |
| requires |
NADPH
ⓘ
cytochrome P450 reductase NERFINISHED ⓘ |
| subcellularLocation | microsome ⓘ |
| usesSubstrate | lipophilic compounds ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: CYP3A5 Description of subject: CYP3A5 is a liver-expressed cytochrome P450 enzyme that metabolizes various drugs and xenobiotics, contributing to interindividual variability in drug clearance.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Docetaxel